{"prompt": "['Abbreviated Title: Ph II SGI110 in Peds & Adults', '37', 'Version Date: 07/22/2019', \"measurements recorded since the treatment started). The patient's best response assignment will\", 'depend on the achievement of both measurement and confirmation criteria.', 'For Patients with Measurable Disease (i.e., Target Disease)', 'Target', 'Non-Target', 'New', 'Overall', 'Best Overall Response when', 'Lesions', 'Lesions', 'Lesions', 'Response', 'Confirmation is Required*', 'CR', 'CR', 'No', 'CR', '>4 wks. Confirmation**', 'CR', 'Non-', 'No', 'PR', 'CR/Non-PD', 'CR', 'Not', 'No', 'PR', 'evaluated', '>4 wks. Confirmation**', 'PR', 'Non-', 'No', 'PR', 'CR/Non-', 'PD/not', 'evaluated', 'SD', 'Non-', 'No', 'SD', 'CR/Non-', 'Documented at least once >4', 'PD/not', 'wks. from baseline**', 'evaluated', 'PD', 'Any', 'Yes or', 'PD', 'No', 'Any', 'PD***', 'Yes or', 'PD', 'no prior SD, PR or CR', 'No', 'Any', 'Any', 'Yes', 'PD', '*', 'See RECIST 1.1 manuscript for further details on what is evidence of a new lesion.', '**', 'Only for non-randomizedtrials with response as primary endpoint.', 'In exceptional circumstances, unequivocal progression in non-target lesions may be acceptedas', 'disease progression.', 'Note:', 'Patients with a global deterioration of health status requiring discontinuation of treatment without', 'objective evidence of disease progression at that time should be reportedas \"symptomatic', 'deterioration. Every effort should be made to document the objective progression even after', 'discontinuation of treatment.', 'For Patients with Non-Measurable Disease (i.e., Non-Target Disease)', 'Non-TargetLesions', 'New Lesions', 'Overall Response', 'CR', 'No', 'CR', 'Non-CR/non-PD', 'No', 'Non-CR/non-PD', '*', 'Not all evaluated', 'No', 'not evaluated', 'Unequivocal PD', 'Yes or No', 'PD', 'Any', 'Yes', 'PD', '*', '\"Non-CR/non-PD is preferred over \\'stable disease\\' for non-target disease since SD is increasingly used', 'as an endpoint for assessment of efficacy in some trials: so to assign this category when no lesions can be', 'measured is not advised', '8.2.3', 'Duration of Response']['Abbreviated Title: Ph II SGI110 in Peds & Adults', '38', 'Version Date: 07/22/2019', 'Duration of overall response: The duration of overall response is measured from the time', 'measurement criteria are met for CR or PR (whichever is first recorded) until the first date that', 'recurrent or progressive disease is objectively documented (taking as reference for progressive', 'disease the smallest measurements recorded since the treatment started).', 'The duration of overall CR is measured from the time measurement criteria are first met for CR', 'until the first date that progressive disease is objectively documented.', 'Duration of stable disease: Stable disease is measured from the start of the treatment until the', 'criteria for progression are met, taking as reference the smallest measurements recorded since the', 'treatment started, including the baseline measurements.', '9', 'ADVERSE EVENTS: LIST AND REPORTING REQUIREMENTS', '9.1', 'COMPREHENSIVE ADVERSE Event AND POTENTIAL RISKLIST (CAEPRS)', '9.1.1 Comprehensive Adverse Events and Potential Risks list (CAEPR for SGI-110 (NSC', '780463)', 'The Comprehensive Adverse Events and Potential Risks list (CAEPR) provides a single list of', 'reported and/or potential adverse events (AE) associated with an agent using a uniform', 'presentation of events by body system. In addition to the comprehensive list, a subset, the', 'Specific Protocol Exceptions to Expedited Reporting (SPEER), appears in a separate column and', 'is identified with bold and italicized text. This subset of AEs (SPEER) is a list of events that are', 'protocol specific exceptions to expedited reporting to NCI (except as noted below). Refer to the', \"'CTEP, NCI Guidelines: Adverse Event Reporting Requirements'\", 'http://ctep.cancer.gov/protocolDevelopment/electronic applications/docs/aeguidelines.pdf for', 'further clarification. Frequency is provided based on 757 patients. Below is the CAEPR for SGI-', '110 (Guadecitabine).', 'NOTE: Report AEs on the SPEER ONLY IF they exceed the grade noted in parentheses next to', 'the AE in the SPEER. If this CAEPR is part of a combination protocol using multiple', 'investigational agents and has an AE listed on different SPEERs, use the lower of the grades to', 'determine if expedited reporting is required.', 'Version 2.1, May 8, 2019\u00b9', 'Adverse Events with Possible', 'Relationship to SGI-110 (Guadecitabine)', 'Specific Protocol', '(CTCAE 5.0 Term)', 'Exceptions to Expedited', '[n= 757]', 'Reporting (SPEER)', 'Rare but Serious', 'Likely (>20%)', 'Less Likely (<=20%)', '(<3%)', 'BLOOD AND LYMPHATIC SYSTEM DISORDERS', 'Anemia', 'Anemia (Gr 2)', 'Febrile neutropenia', 'Febrile neutropenia (Gr 2)', 'EYE DISORDERS']\n\n###\n\n", "completion": "END"}